|1.||Malamud, Daniel: 2 articles (10/2013 - 04/2005)|
|2.||Rountree, Wes: 2 articles (01/2008 - 01/2007)|
|3.||Nanda, Kavita: 2 articles (01/2008 - 01/2007)|
|4.||Krebs, Fred C: 2 articles (09/2005 - 04/2005)|
|5.||Miller, Shendra R: 2 articles (09/2005 - 04/2005)|
|6.||Catalone, Bradley J: 2 articles (09/2005 - 04/2005)|
|7.||Wigdahl, Brian: 2 articles (09/2005 - 04/2005)|
|8.||Howett, Mary K: 2 articles (09/2005 - 04/2005)|
|9.||Song, Chang-Seon: 1 article (07/2014)|
|10.||Kang, Byung-Hwa: 1 article (07/2014)|
10/01/2013 - "C31G and TFT were very effective in reducing the lesions and pathogenesis associated with HSV-1 ocular keratitis. "
10/01/2013 - "The antimicrobial agent C31G is effective for therapy for HSV-1 ocular keratitis in the rabbit eye model."
10/01/2013 - "No previous in vivo studies have been done to test C31G in an animal model of HSV-1 ocular keratitis. "
|2.||Human Influenza (Influenza)
|3.||Acquired Immunodeficiency Syndrome (AIDS)
|4.||HIV Infections (HIV Infection)
01/01/2008 - "The objective of this trial was to determine the effectiveness of 1.0% C31G (SAVVY) in preventing male-to-female vaginal transmission of HIV infection among women at high risk. "
01/01/2007 - "The objective of this trial was to determine the effectiveness of 1.0% C31G (SAVVY) in preventing male-to-female vaginal transmission of HIV infection among women at high risk. "
01/01/2007 - "SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana."
01/01/2008 - "SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria."
02/01/2004 - "Glyminox (Savvy) is a vaginal gel formulation of C31G being developed by Biosyn as a potential contraceptive and for the potential prevention of transmission of sexually transmitted diseases, including HIV infection. "
|5.||Wounds and Injuries (Trauma)
01/01/1986 - "At 7, 10, and 16 days after surgery, tensiometric measurements of C31G (a surfactant)-treated wounds were 99%, 139%, and 195% of control wound values, respectively. "
07/01/1983 - "In this animal model, histologic features of wounds treated topically with C31G revealed an increased rate of wound closure associated with decreased inflammatory response and increased C31G fibroblast infiltration and epithelialization. "
07/01/1983 - "An anti-infective surfactant composition (C31G) promoted healing of infected and noninfected wounds in guinea pigs. "
07/01/1983 - "Effect of C31G, an antimicrobial surfactant, on healing of incised guinea pig wounds."
02/01/1983 - "The early events in the repair process indicated a greater degree of inflammatory response comprised mainly of polymorphonuclear leukocytes with subsequent large numbers of monocytes in C31G and alkyl amine oxide-treated wounds. "
|3.||PRO 2000 (PRO-2000)
|5.||Sodium Chloride (Saline Solution)
|6.||Vaginal Creams, Foams, and Jellies (Vaginal Tablet)
|7.||chlorine dioxide (Alcide)